Comments on "an innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective n-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder"

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 411-412

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IFENPRODIL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAROXETINE; PLACEBO; TRAXOPRODIL;

ABNORMAL BEHAVIOR; ABNORMAL LABORATORY RESULT; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HAMILTON SCALE; HUMAN; LETTER; MAJOR DEPRESSION; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE ODOR; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; PAROXETINE; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SIGMA; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 68449103046     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ace848     Document Type: Letter

References (11)

1. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631-637.
2. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev Drug Discov. 2008;7:426-437.
3. Krystal JH. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly. 2007;137:215-216.
4. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
5. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
6. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
7. 3H] ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol. 1993;236:159-163.
8. 3H]ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D- aspartate receptors containing NR2B subunits. J Pharmacol Exp Ther. 2001;296:150-159.
9. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12:3857-3876.
10. Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry. 2008;69:1673-1674.
11. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents - Med Chem. 2009; in press.